No Data
Lyon: Maintains JD HEALTH "Outperform Market" rating with a Target Price of 40 Hong Kong dollars.
Lyon released a Research Report stating that it maintains a "outperform the market" rating for JD HEALTH (06618), with a Target Price of 40 Hong Kong dollars. The bank expects the company's revenue growth to accelerate to 15% this year, predicting that JD HEALTH's performance in the second half of last year remained steady, with revenue increasing by 13% year-on-year to 29.7 billion yuan. Benefiting from the strong performance of the Singles' Day Sales, drug demand remains strong, and with the expansion of gross margin, adjusted EBIT is expected to increase by 23% year-on-year to 1.2 billion yuan. The bank expects the company's direct sales in the second half of last year to increase by 12% year-on-year to 25.3 billion yuan, with fourth-quarter sales rising by 11% year-on-year, and the number of annual active users is expected to increase by 9 million compared to the first half.
China International Capital Corporation: Maintains the "Outperform Industry" rating for old mine Gold, raises the Target Price to HKD 537.55.
China International Capital Corporation released a research report stating that it maintains a "Outperform Industry" rating for Laopu Gold (06181), raising the Target Price by 57% to 537.55 Hong Kong dollars. Considering the company's consistently better-than-expected terminal sales performance, the firm raised its earnings per share forecasts for 2024/2025/2026 by 22%/13%/8% to 8.63/11.78/14.89 yuan respectively. Laopu Gold announced a positive profit forecast for 2024, expecting a net income of approximately 1.4-1.5 billion yuan, a year-on-year increase of 236%-260%. As Laopu Gold's brand power continues to rise and break through boundaries.
Goldman Sachs: Maintains JD HEALTH 'Buy' rating, valuation comparatively more attractive.
Goldman Sachs released a Research Report stating that it maintains a "Buy" rating for JD HEALTH (06618) and a "Neutral" rating for ALI HEALTH (00241), with a Target Price of 4 Hong Kong dollars. From a valuation perspective, Goldman Sachs believes JD HEALTH is more attractive than ALI HEALTH, with expected sales growth of 13%-15% year-on-year over the next two years, and continued expansion of operating profit margins in fiscal year 2025. Goldman Sachs stated that JD HEALTH has a stronger competitive advantage in the pharmaceutical category, achieving online and offline integration through online-to-offline and physical pharmacy layouts, and will benefit from the expansion of online medical insurance reimbursements. Over the next two years, JD
The Recent 16% Gain Must Have Brightened CEO Kun Wang's Week, Wuxi Online Offline Communication Information Technology Co., Ltd.'s (SZSE:300959) Most Bullish Insider
Online and offline (300959.SZ): Currently, there is no direct Business cooperation with DeepSeek.
On February 10, according to Gelonghui, Online and Offline (300959.SZ) stated on the investor interaction platform that the company does not currently have direct Business cooperation with DeepSeek. The company actively pays attention to cutting-edge technologies and seizes development opportunities in line with its own Business planning and Global Strategy direction.
Online and offline (300959.SZ): Repurchase completed. A total of 30.133 million yuan was spent to repurchase 0.5989 million shares.
Gelonghui, January 17丨 Online and offline (300959.SZ) announced that from the date of the Board of Directors' approval of the share buyback plan on November 12, 2024, to January 17, 2025, the company has cumulatively repurchased shares using a dedicated securities account through centralized bidding Trade, totaling 0.5989 million shares, accounting for 0.75% of the company's current total equity, with a highest Fill Price of 53.02 yuan/share, a lowest Fill Price of 38.80 yuan/share, and a total transaction amount of 30.133 million yuan (excluding trading fees). This share buyback plan has been completed, and the actual buyback time has been recorded.
Wuxi Online Offline Communication Information Technology Co., Ltd.'s (SZSE:300959) 25% Share Price Plunge Could Signal Some Risk